STUB1 and myelodysplastic syndrome: CHIP is a potential premalignant phase of myelodysplastic syndrome (MDS), acute myeloid leukaemia or therapy-related myeloid neoplasms and according to the previous publications is associated with a 0.5–1.0% risk per year of leukaemia [78,79].